Matched sibling or alternative donor HCT, orHiDAC 1.5‐3 g/m2 over 3 h every 12 h on days 1, 3, 5 or 1, 2, 3 × 3‐4 cycles, orHiDAC 1.5‐3 g/m2 over 3 h every 12 h on days 1, 3, 5 or 1, 2, 3 with oral midostaurin 50 mg every 12 h on days 8‐21 (FLT3‐mutated AML), orCytarabine 1000 mg/m2 every 12 h on days 1‐4 + daunorubicin 60 mg/m2 on day 1 (first cycle) or days 1‐2 (second cycle) + gemtuzumab ozogamicin 3 mg/m2 on day 1 × 2 cycles (CD33‐positive). Here, CD33 is linked to acute myeloid leukemia.